The North America Onychomycosis Market would witness market growth of 4.2% CAGR during the forecast period (2022-2028).
Onychomycosis can be brought on by a variety of fungi, including Fusarium and dermatophytes. Risk factors include athletes' foot or some other nail/foot conditions, peripheral vascular disease, contact with those who have it, and a weakened immune system. Usually, based on the appearance, the diagnosis is speculated, and laboratory testing is used to confirm it. Numerous kinds of fungi that are present in the environment cause fungus-related nail diseases. These germs can enter the nail through tiny holes in the skin around it or in the nail, inflicting an infection.
The most effective course of treatment for fungus nail infections is to begin early, frequently through oral administration of prescription antifungal medications. In extreme circumstances, a medical practitioner might fully remove the nail. However, the illness may take a few months to one year to clear up. Fungal skin infections can often occur with fungal nail infections. In addition, the fungal infection spreads from one location to another if it is not treated. Fungal infections can recur even after therapy.
The prevalence of diabetes and the aging population in the region are the primary factors propelling the region's onychomycosis treatment demand. More than 3 million Canadians are diagnosed to be suffering from diabetes. Moreover, in 2016, the Census Bureau estimated that there were around 49.2 million Americans who were 65 or older, with one-fourth of them residing in one of the three states of California, Florida, or Texas. Seven additional states—Georgia, Illinois, Michigan, and New York—make up another quarter of the population aged 65 and over. This supports the growth of the regional market.
The US market dominated the North America Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,287.9 Million by 2028. The Canada market is poised to grow at a CAGR of 6.5% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 5.6% during (2022 - 2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Onychomycosis Market is Predict to reach $4.5 Billion by 2028, at a CAGR of 4.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
By Type
By Treatment
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 